Fueling Innovation: KickStart Venture Services Celebrates Startups

KickStart Commercialization Grants bolster UNC startups with critical early-stage funding. Since its inception, the grants program has invested more than $3.1 million in 76 startups.

KVS_Awards_Spring_2025
March 13, 2025
By Shellie Edge
Photography by Brock Pierce

KickStart Venture Services (KVS), a department within Innovate Carolina that supports intellectual-property based startups, has awarded $326,000 in commercialization grants to seven University of North Carolina at Chapel Hill affiliated startup companies. KickStart Commercialization Grant Awards play a crucial role in advancing Carolina-based innovations, helping early-stage startups translate university-developed intellectual property into market-ready technologies. 

Over the past 15 years, the grant award program has provided more than $3.1 million in early-stage funding, contributing to the success of more than 76 startups that have collectively raised more than $1 billion in follow-on funding. The grants—ranging up to $50,000 each—are part of a university-wide effort to move discoveries from UNC-Chapel Hill’s academic laboratories into products and services that benefit society.

“High-potential ventures need the necessary support to succeed,” says Dedric A. Carter, PhD, MBA, Chief Innovation Officer and Vice Chancellor of Innovation, Entrepreneurship & Economic Development at UNC-Chapel Hill. “The Kickstart Commercialization Grants program strengthens resource allocation, technical assistance and support, helping startups mitigate early-stage risks and accelerate commercialization—ultimately increasing the likelihood of venture success.”

Beyond grants, KVS offers startup founders a robust suite of resources to help accelerate their company’s growth. Kickstart offers mentorship, business strategy support, educational resources, and engagement opportunities with industry experts, entrepreneurial leaders, and investors. KVS also leads UNC-Chapel Hill’s regional National Science Foundation’s I-Corps program, guiding early-stage startups in validating market demand for their innovations.

“The KickStart Commercialization Grant Awards play a vital role in translating promising research and technologies from UNC-Chapel Hill,” says Mireya McKee, PhD, director of KVS. “The award helps founders move transformative ideas from the lab to market by funding key technical milestones, validating their innovations, and positioning them for future investment and growth. By supporting ventures at such a pivotal stage, we’re strengthening our ecosystem and accelerating the impact of Carolina’s research on society.”

Additionally, the on-campus KVS Accelerator provides flexible wet lab and office space equipped with shared research tools, cubicles, meeting rooms, and collaborative workspaces—offering startups the infrastructure they need to thrive.

“We are thrilled to celebrate the 2025 grant recipients and the impact they will have on the future of innovation. These ventures are at the forefront of cutting-edge research, and we look forward to seeing their groundbreaking work translate into real-world solutions that drive economic and societal progress.,” adds McKee.

179 companies
funded or advised since 2009
$317.5 million
total federal SBIR/STTR grants secured
2,358
people employed by KickStart companies

2025 Grant Recipients

AmarnaBio | $50K award 
AmarnaBio aims to revolutionize precision medicine by leveraging computational algorithms, including artificial intelligence/machine learning (AI/ML), to gain insights into genomic dark matter for biomedical applications. Their core technology focuses on noncoding sequence, which is more prevalent than protein-coding sequence in the human genome and is a largely untapped resource. 

Delgen Biosciences |$50K award
Delgen Biosciences is a preclinical biotech company in new drug development founded in 2020 by a UNC faculty member in polymer chemistry. The company was founded based on a novel polymer platform developed in Dr. Wei You’s laboratory at UNC-Chapel Hill and supported by the KickStart Accelerator Program. The company set out to commercialize the polymer platform and develop the next-generation drug delivery technology, which has the potential to become an alternative therapeutic modality for future precision medicine. Its initial product is an ophthalmic drug for the benefit of millions of age-related macular degeneration patients.

Epigenos Biosciences | $50K award
While AAV-based vectors have shown immense promise as gene delivery platforms in several therapeutic applications, one major limitation is the inability to regulate therapeutic (transgene) expression post-administration. This constraint can hinder therapeutic outcomes, as optimal gene expression levels are often not achieved, leading to either subtherapeutic expression, toxic levels of therapeutic gene overexpression, or the need for high viral doses, which may induce immune responses. To address these challenges, Epigenos Biosciences, founded by UNC-Chapel Hill Associate Professor Dr. Nate Hathaway, has created a new generation AAV-based vector system, CEMTrol, that contains a unique genetic element that will enable, for the first time, adjustable, controllable gene dosage, which will allow personalized treatments tailored to patient needs and safety concerns. Epigenos is leveraging the CEMTrol system to develop gene therapies for rare diseases in which precise levels of gene expression are required for safe and effective treatment. 

ForagR Medicines | $50K award
ForagR Medicines is a UNC spin out company focused on making a new class of drugs that target the messenger RNAs that tell cells how to make proteins. The vast majority of drugs ever developed target proteins, but there are many classes of proteins that just cannot be drugged in the conventional way. ForagR is focusing on major opportunities for neurological diseases and in cancer. ForagR uses technologies invented in the laboratory of chemistry professor Kevin Weeks, that are being developed by Dr. Jordan Koehn, who wants to translate the innovative work he did as a postdoc at UNC into new medicines with broad impact.

Sorbenta, Inc. | $50K award
Sorbenta, Inc. is dedicated to developing innovative sorbents that effectively remove harmful ‘forever chemicals’ known as PFAS from a broad range of waters globally. Sorbenta’s goal is to provide effective water treatment solutions that protect both public health and the environment. Sobenta’s patent-protected innovations enable effective removal of both short-chain and long-chain PFAS of diverse chemistries, and the sorbents are drop-in replacements for ion exchange resins and are compatible with existing water treatment infrastructure, enabling seamless technology transition.

Persistence Therapeutics | $50K award
Persistence Therapeutics is a trailblazing biotechnology company with a mission to redefine cellular immunotherapy for cancer patients, capitalizing on issued and filed intellectual property for novel device technology.  Persistence is developing unique, biocompatible sponges the size of a dime. Dubbed SynthNode, the implanted sponge mimics a synthetic lymph node, where anti-cancer cells are produced, proliferate, exit the device, traffic to the patient’s tumor to annihilate cancer cells. This robust technology provides rapid, potent, and cost-efficient delivery of anti-cancer cells, including autologous or allogeneic chimeric antigen receptor (CAR) T cells, and NK cells.

LevoSens | $26K award
LevoSens is a MedTech start up founded by Dr. Koji Sode, Dr. David Probst, and Bioventure Partners out of the Lampe joint department of Biomedical engineering at UNC-Chapel Hill and North Carolina State. The core mission of LevoSens is to empower individuals with Parkinson’s disease by providing innovative biosensing solutions that enhance control and restore freedom in their daily lives. To achieve this goal, LevoSens has developed innovative biosensors for both discrete and continuous monitoring of levodopa, the primary therapy in treating Parkinson’s disease. Using these biosensors, patients and clinicians will, for the first time, have a quantitative tool giving feedback on levodopa therapy, helping to alleviate the poor outcomes associated with under/over titrating of levodopa. The KVS grant will help LevoSens reach specific technical and business development milestones toward translating the biosensor for patient use.

The KickStart Commercialization Grant Awards program is open to early-stage companies based on research innovations for which at least one founder is a faculty member, student or staff person at UNC-Chapel Hill.